PBGH Announcements


May 6, 2020

Poll: Large Employers Consider a Range of Methods to Safely Return Employees to Work Post COVID-19

Most major employers are embracing social distancing and other measures to safely bring employees back to work amid the new normal imposed by COVID-19, a recent Pacific Business Group on Health poll showed. See the results here.

April 26, 2020

PBGH issues statement on the passage of the CARES Act – COVID-19 Response Package

The Coronavirus Aid, Relief, and Economic Security Act (S. 3548; H.R. 748), passed by Congress and signed into law today, is a very important step in the right direction at addressing the immediate needs of businesses and individuals. In this policy statement, PBGH calls on Congress and the Administration as it develops the next anticipated COVID-19 package to include the following provisions.

April 17, 2020

PBGH urges Secretary Azar to protect primary care practices

In a letter to Health and Human Services Secretary Alex Azar, the Pacific Business Group on Health calls on the Trump administration to address the urgent need to protect and strengthen independent primary care practices during the COVID-19 pandemic.

April 16, 2020

Protecting Primary Care in California During COVID-19 Pandemic

The Pacific Business Group on Health, as part of a coalition of physicians, consumer and business leaders, is calling on California state legislators to protect the very foundation of our health care system by supporting independent primary care providers vulnerable to the huge economic impacts of the COVID-19 pandemic.

March 16, 2020

PBGH Announces Shawn Gremminger as Director, Health Policy

Pacific Business Group on Health (PBGH) is pleased to announce Shawn Gremminger as Director, Health Policy beginning on March 16, 2020.

February 24, 2020

Employers Support Bipartisan Bill to Increase Drug Price Transparency and Reduce Gaming by Middlemen

Employers’ Prescription for Affordable Drugs (EmployersRx) has announced its support of H.R. 5304, the “PBM Transparency and Prescription Drug Costs Act.” This bipartisan legislation will markedly lower private health insurance premiums and increase competition in the marketplace, according to a July 2019 report from the Congressional Budget Office.

February 7, 2020

Statement of Record for House Committee on Ways and Means, Subcommittee on Health

Chairman Doggett, Ranking Member Nunes, and members of the House Ways and Means Health Subcommittee, thank you for the opportunity to provide a written statement for today’s hearing on behalf of the Employers’ Prescription for Affordable Drugs (EmployersRx), a coalition of employers united in advocacy to drive down the cost of prescription drugs—one of the biggest challenges in health care.

February 4, 2020

No More ‘Sucker at the Table’: New Coalition to Represent Fortune 500 Firms Paying Prescription Drug Bills

Tired of being “the sucker at the table,” a group representing Fortune 500 companies has formed a lobby to push congressional drug-pricing policies that focus beyond Medicare. Employers’ Prescription for Affordable Drugs has described its goal as “to mobilize large employers to drive down prescription drug costs by advocating for public policies based on increased competition, transparency and value.”

February 3, 2020

Employers Shoulder Plenty of Drug Costs, but Haven’t Lobbied Much to Lower Them — Until Now

Legislation aiming to reduce drug prices has thus far focused on changes to federal programs such as Medicare. But Walmart, Pepsi, and other large companies provide employer-sponsored health insurance to more than 150 million Americans, making them the largest footers of health bills.

January 21, 2020

Coalition Advocates for Biosimilar Uptake to Help Lower Employers’ Drug Cost Burden

Rising drug costs in the United States are a pressing concern not only for patients who need to receive those drugs, but also for employers. The Employers’ Prescription for Affordable Drugs (EmployersRx) is a coalition that aims to tackle this problem by working with policy makers and stakeholders to encourage and facilitate more transparency, competition, and value in the healthcare system.